One health care stock that insiders are loading up on here is Karyopharm Therapeutics (KPTI_), which focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Insiders are buying this stock into major weakness, since shares are down by 31% over the last three months.
Karyopharm Therapeutics has a market cap of $817 million and an enterprise value of $641 million. This stock trades at a premium valuation, with a price-to-book of 5.64. Its estimated growth rate for this year is 63.7%, and for next year it's pegged at -54.2%. This is a cash-rich company, since the total cash position on its balance sheet is $144.89 million and its total debt is zero
...and its burning cash with significant losses, and some very expensive quarters coming up. I would think the company may consider a secondary to take advantage of the current pps. Company has a long expensive road ahead.
Operating Margin (ttm): -12,938.77%
Operating Cash Flow (ttm): -35.70M
Revenue Per Share (ttm): 0.03
Qtrly Revenue Growth (yoy): -26.60%
EBITDA (ttm)6: -41.90M
Net Income Avl to Common (ttm): -42.03M
Diluted EPS (ttm): -3.26
Return on Equity (ttm): -58.59%